This paper explores the complex connections among intellectual property protection, competition, and access to affordable prescription drug products. It focuses on several provisions of the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman) and discusses the debate swirling around its reform. An overview of landmark intellectual property laws and a description of the generic drug approval process are also included
Much of the extensive commentary on the six month coexclusivity period allowed by the Hatch-Waxman A...
This article discusses how pharmaceutical innovation achieves remarkable improvements in human healt...
The evolution of pharmaceutical competition since Congress passed the Hatch-Waxman Act in 1984 raise...
Recently there has been a considerable amount of pressure to accelerate consumer access to generic d...
The Hatch-Waxman Act of 1984 aims to strike a balance between the innovation incentives provided by ...
The Hatch-Waxman Act was intended to establish a balance between the competing interests of brand na...
The Hatch-Waxman Act of 1984 established a system whereby generic manufacturers can seek to market g...
When generic drugs seek FDA approval, the pharmaceutical company files an Abbreviated New Drug Appli...
Recently there has been a considerable amount of pressure to accelerate consumer access to generic d...
Without a doubt, health care costs are on the rise, and how to reduce those costs is of great concer...
International audienceThe evolution of pharmaceutical competition since Congress passed the Hatch-Wa...
International audienceThe evolution of pharmaceutical competition since Congress passed the Hatch-Wa...
The Hatch-Waxman Act of 1984 aims to strike a balance between the innovation incentives provided by ...
The Hatch-Waxman Act of 1984 aims to strike a balance between the innovation incentives provided by ...
One of Congress\u27 central goals in enacting the Hatch-Waxman Act was to expedite and encourage ear...
Much of the extensive commentary on the six month coexclusivity period allowed by the Hatch-Waxman A...
This article discusses how pharmaceutical innovation achieves remarkable improvements in human healt...
The evolution of pharmaceutical competition since Congress passed the Hatch-Waxman Act in 1984 raise...
Recently there has been a considerable amount of pressure to accelerate consumer access to generic d...
The Hatch-Waxman Act of 1984 aims to strike a balance between the innovation incentives provided by ...
The Hatch-Waxman Act was intended to establish a balance between the competing interests of brand na...
The Hatch-Waxman Act of 1984 established a system whereby generic manufacturers can seek to market g...
When generic drugs seek FDA approval, the pharmaceutical company files an Abbreviated New Drug Appli...
Recently there has been a considerable amount of pressure to accelerate consumer access to generic d...
Without a doubt, health care costs are on the rise, and how to reduce those costs is of great concer...
International audienceThe evolution of pharmaceutical competition since Congress passed the Hatch-Wa...
International audienceThe evolution of pharmaceutical competition since Congress passed the Hatch-Wa...
The Hatch-Waxman Act of 1984 aims to strike a balance between the innovation incentives provided by ...
The Hatch-Waxman Act of 1984 aims to strike a balance between the innovation incentives provided by ...
One of Congress\u27 central goals in enacting the Hatch-Waxman Act was to expedite and encourage ear...
Much of the extensive commentary on the six month coexclusivity period allowed by the Hatch-Waxman A...
This article discusses how pharmaceutical innovation achieves remarkable improvements in human healt...
The evolution of pharmaceutical competition since Congress passed the Hatch-Waxman Act in 1984 raise...